These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 30296806)
21. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. van Duin D; Bonomo RA Clin Infect Dis; 2016 Jul; 63(2):234-41. PubMed ID: 27098166 [TBL] [Abstract][Full Text] [Related]
22. Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam. Li J; Lovern M; Riccobene T; Carrothers TJ; Newell P; Das S; Talley AK; Tawadrous M Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015049 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia. Falcone M; Viale P; Tiseo G; Pai M Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):331-340. PubMed ID: 29373935 [TBL] [Abstract][Full Text] [Related]
24. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. Falcone M; Paterson D J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868 [TBL] [Abstract][Full Text] [Related]
28. A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects. Li J; Learoyd M; Qiu F; Zhu L; Edeki T Clin Drug Investig; 2016 Feb; 36(2):119-26. PubMed ID: 26649741 [TBL] [Abstract][Full Text] [Related]
29. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria. Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of the post-antibiotic effect Berkhout J; Melchers MJ; van Mil AC; Lagarde CM; Nichols WW; Mouton JW J Chemother; 2021 Oct; 33(6):400-408. PubMed ID: 33682636 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis. Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670 [TBL] [Abstract][Full Text] [Related]
32. Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups. Li J; Lovern M; Green ML; Chiu J; Zhou D; Comisar C; Xiong Y; Hing J; MacPherson M; Wright JG; Riccobene T; Carrothers TJ; Das S Clin Transl Sci; 2019 Mar; 12(2):151-163. PubMed ID: 30221827 [TBL] [Abstract][Full Text] [Related]
33. Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections. Chahine EB; Sourial M; Ortiz R Consult Pharm; 2015 Dec; 30(12):695-705. PubMed ID: 26671269 [TBL] [Abstract][Full Text] [Related]
34. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Liscio JL; Mahoney MV; Hirsch EB Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591 [TBL] [Abstract][Full Text] [Related]
35. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota. Rashid MU; Rosenborg S; Panagiotidis G; Löfdal KS; Weintraub A; Nord CE Int J Antimicrob Agents; 2015 Jul; 46(1):60-5. PubMed ID: 25979639 [TBL] [Abstract][Full Text] [Related]
36. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Mawal Y; Critchley IA; Riccobene TA; Talley AK Expert Rev Clin Pharmacol; 2015; 8(6):691-707. PubMed ID: 26420166 [TBL] [Abstract][Full Text] [Related]
37. Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. Tominaga N; Edeki T; Li J; Learoyd M; Bouw MR; Das S J Infect Chemother; 2015 Aug; 21(8):551-8. PubMed ID: 26076867 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration. Wenzler E; Bunnell KL; Bleasdale SC; Benken S; Danziger LH; Rodvold KA Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416553 [TBL] [Abstract][Full Text] [Related]
39. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]